865 reports of this reaction
2.5% of all MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE reports
#6 most reported adverse reaction
COUGH is the #6 most commonly reported adverse reaction for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, manufactured by Organon LLC. There are 865 FDA adverse event reports linking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE to COUGH. This represents approximately 2.5% of all 35,067 adverse event reports for this drug.
Patients taking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COUGH is a less commonly reported adverse event for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, but still significant enough to appear in the safety profile.
In addition to cough, the following adverse reactions have been reported for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE:
The following drugs have also been linked to cough in FDA adverse event reports:
COUGH has been reported as an adverse event in 865 FDA reports for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COUGH accounts for approximately 2.5% of all adverse event reports for MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, making it a notable side effect.
If you experience cough while taking MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.